| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Decrease in cash, cash equivalents and restricted cash and restricted cash equivalents | -5,070 | -5,409 |
| Cash and cash equivalents at beginning of period | 6,707 | - |
| Cash and cash equivalents at end of period | 1,637 | - |
Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc. (APTOF)